China SXT Pharmaceuticals Commences ~$9M Offering Of 4.5M Class Ordinary Shares At $3.20/Share

China SXT Pharmaceuticals Inc. (NASDAQ:SXTC) (the "Company"), today announced that it has entered into a definitive securities purchase agreement with certain institutional investors for the purchase and sale of an aggregate of 4,500,000 units (each, a "Unit"), consisting of one Class A ordinary share of the Company, no par value per share (each, a "Class A ordinary share"), and one common warrant (each, a "Warrant"), at a purchase price of $2.00 per Unit in a registered direct offering.

Each of the Warrants will have an exercise price of $3.20 per Class A Class A ordinary share, will be immediately exercisable upon issuance, and will expire on the one year anniversary of the issuance date. The aggregate gross proceeds to the Company of this offering are expected to be approximately $9 million, before deducting placement agent fees and other offering expenses payable by the Company. The transaction is expected to close on or about July 24, 2025, subject to the satisfaction of customary closing conditions.